A mean increase of only 50 cells per cubic mm, from Schering's CCR5 receptor antagonist candidate, vicriviroc. That's a press release-worthy item, according to Kenilworth? Color me curious, here:
. . . .The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period. . . .
No comments:
Post a Comment